Medicine & Health

Publication Search Results

Now showing 1 - 3 of 3
  • (2022) Sotade, Dami
    Aortic valve replacement is the standard treatment for severe aortic stenosis and aortic regurgitation. Internationally and in Australia, there is limited clinical trial evidence for valve devices, and scant information about real-world use, benefits and harms once these devices are adopted into clinical practice. Data generated by the routine operation of health systems are being employed increasingly to provide real-world evidence for the study of valve devices. Longitudinal and population-level data generated within the Australian health system provides a unique opportunity to investigate the use and outcomes of aortic valve devices. This thesis profiles the use of aortic valve replacement (AVR) procedures — including surgical aortic valve replacement (SAVR) and the newer, less-invasive, transcatheter aortic valve implantation (TAVI)— in the population of New South Wales (NSW), Australia. It addresses important evidence gaps, including: (i) how the use of AVR devices has changed over time; (ii) whether there are differences in patient outcomes between types of valve prostheses: mechanical valves (MV) and bioprosthetic valves (BV); and (iii) whether patients are receiving guideline-recommended antithrombotic medicines following TAVI. The analyses reported here identified changing trends over time in the type of SAVR procedures being used in NSW between 2001-2013, with increasing use of BV (from 9 to 18 per 100,000 population ) and decreasing use of MV (7 to 4 per 100,000 population). TAVI is now established as the new standard of care among patients aged over 80 years, although it is also being increasingly used in younger patients, particularly those funded privately. Comparative analyses of age-specific incidence rates of clinical outcomes for patients implanted with BV and MV found that after 5 years of follow-up, patients aged 18-64 years who were implanted with BV had higher rates of reoperation, but lower rates of stroke and haemorrhage. Among patients aged 65+ years, those implanted with BV had lower rates of acute myocardial infarction (AMI), haemorrhage and mortality. After 6-10 years of follow-up, rates of AMI were lower among patients aged 18-64 years implanted with BV, and among patients aged 65+ years, rates of cardiovascular and all-cause mortality remained significantly lower for patients implanted with BV. Further analyses for patients aged <65 years found further age-specific differences in risks of reoperation and mortality over time: patients aged 18-54 years who received BV were consistently at greater risk of reoperation over 15-years of follow-up, whereas patients aged 55-64 years only had a greater risk of reoperation beyond 10 years. Although there was no difference in mortality by valve type in patients aged 18-54 years, patients aged 55-64 years who received BV had a greater risk of mortality after 10 years of follow-up. Finally, analyses of post-TAVI dispensing found that one-third of patients receiving TAVI were not dispensed guideline-recommended antithrombotic therapy, within 30-days of discharge. The strongest predictor of dispensing was prior exposure to antithrombotic medicines, suggesting that there may be potential gaps in adherence to clinical guidelines for patients who are new to the therapy. These findings highlight the importance of monitoring the use and outcomes of aortic valve devices in the long-term. They also demonstrate how routinely collected data sources, used in combination with appropriate methods, can offer valuable insight into clinical practice relating to medical devices. Real-world evidence generated using these data complement clinical trials and registries, offering a scalable solution for the challenges of evaluating device-related outcomes in the long-term.

  • (2021) Zhu, Elliott
    The central aim of this thesis is concerned with the elucidation of cause-effect relationships from observational data among variables or events in the context of personalised healthcare. Appropriate methodology for extracting such relationships has been developed and discussed within the scope of longitudinal survival analysis. The thesis rethinks two fundamental questions of causality: (1) What empirical evidence is required for legitimate inference of cause-effect relationships? (2) Given that we are willing to accept causal information about a phenomenon, how can we draw inferences from such information? These questions have been without satisfactory answers in the light of observational healthcare, in part because we have not had clear definitions for the causal effect given the ever complex data structure and clinical questions on the unobserved outcome of survival probability, and in part because we have not had effective mathematical tools for deriving individualised causal answers to these questions. In the last decade, owing partly to advances in machine learning models, causality has undergone a major transformation: from a concept shrouded in properly designed randomised experiments into a mathematical object with well-defined semantics which can potentially be identified from observational data. This development has significantly brought down the cost of personalised healthcare in both medication discovery and evaluation. This thesis provides a systematic account of this causal transformation, addressed primarily to epidemiologists, particularly the pharmacoepidemiologist. Following a description of the conceptual and mathematical languages used in causal inference, this thesis emphasizes the development of practical methods for elucidating potentially causal relationships from (longitudinal) observational data, estimating the effects of treatment, and providing recommendations of treatments based on observed scenarios. I have tried in this thesis to present machine learning tools that handle causal relationships side by side with statistical probability theory. The prerequisites are startlingly simple, the results are straightforward. No more than basic skills in probability theory and some familiarity with machine learning are needed for the reader to begin solving causal problems that are too complex for the unaided intellect. The sequence of discussion follows more or less the chronological order by which I have tackled these topics, thus recreating for the reader the sense of progress that accompanied these developments. Following the introductory chapter (Chapter 1), I start with the formal description and review of the mathematical language of causal inference, in particular, how one can go about discovering cause-effect relationships using observational data (Chapter 2). I then proceed to the question of the definition of treatment effect on time-to-event outcomes. In particular, a framework of heterogeneous treatment effect estimation in survival analysis is provided to estimate the effects of static binary treatment conditions on a range of time-to-event outcomes encountered in the healthcare context (Chapters 3 and 4). The framework is then discussed in Chapters 5 and 6 with a more complex data stream, first in the case of time-varying confounders and exposures and then in the contingency of stochastic treatment options, where I examine the concepts of survival treatment effect given longitudinal confounding as well as the contour of time-varying survival dose response function. Chapter 7 offers an application of treatment effect estimation models in a recommendation system, where I used extensive simulations and case studies to demonstrate the advantage of an explanatory model over a predictive model in providing optimal treatment recommendations to patients. I end this thesis with the pursuit of the viability of causal exploration in public health management in Chapter 8, where a case study aiming to answer the question of the effect of public health interventions during the recent SARS-COV-2 pandemic is presented. The work shows that when there is a lack of quality observational data, approaches based on the potential outcomes theory (including the projects presented in Chapters 3 to 7) may fail to make a valid inference and additional assumptions have to be made on the functional form of the causal process. Together, my thesis bridges studies in causal inference theory and machine learning methods in the context of observational healthcare. Significant progress has been made in the development of estimation frameworks for individualised treatment effects subject to longitudinal data with informative censoring. I aim to provide pragmatic insights on the applications and limitations of advanced machine learning models in relation to empirical evidence and draw a clear distinction between causal discovery and conventional predictive learning in the realm of public health and epidemiology.

  • (2023) Bharat, Chrianna
    Despite strong evidence for the effectiveness of a range of interventions to improve the health and wellbeing of people who are dependent on opioids, morbidity and mortality in this population remains higher than that of the general population. There is a need for innovative approaches to monitor and improve the quality use and safety of available medicines, and to better understand risk factors impacting adverse outcomes in this population. In this thesis, routinely collected administrative data on people with opioid dependence in New South Wales (NSW), Australia, were used to investigate medicine use, including Opioid Agonist Treatment (OAT), opioid analgesics, and other psychotropic medicines. Studies in this thesis examined novel methodological approaches to evaluate medicine exposure and quantify risk, both observed and predicted. This thesis used a diverse range of data sources, including controlled drug registries and pharmaceutical claims databases, linked with health service use and mortality records; and implemented a range of statistical methodologies, including generalised estimating equations, Cox proportional hazards models, and deep learning algorithms. Specifically, this thesis aimed to: (i) estimate retention in OAT and identify person, treatment, and prescriber characteristics that are associated with retention; (ii) develop, evaluate and compare models predicting OAT cessation risk at entry to treatment; (iii) examine trends in opioid analgesic utilisation during periods in and out of OAT; (iv) review methods for generating exposure periods from pharmaceutical dispensing data; and (v) evaluating the all-cause and cause-specific mortality risk associated with opioid analgesics, benzodiazepines, gabapentinoids, and OAT. The first study found retention in OAT to be affected not only by characteristics of the person and their treatment, but also of their prescriber, with longer prescribing tenure associated with increased retention of people in OAT. The results from the second study indicated time-to-event prediction models may be limited in their ability to identify individuals at high cessation risk on entry to OAT. Of the methods used in model development, machine learning approaches performed similarly to traditional statistical methods. In the third study, people with opioid dependence were found to have high rates of recent psychotropic medicine utilisation at the time of opioid analgesic initiation, and reduced opioid analgesic dispensing while engaged in OAT. The fourth study describes a novel method for generating medicine exposure periods from dispensing claims data, developed especially for application to medicines with complex and variable dosing regimens. Finally, in the fifth study, benzodiazepines and gabapentinoids appear to increase mortality risk when used in combination with opioid analgesics, although the risk may be reduced when engaged in OAT. This thesis demonstrates the utility of person-level data linkage and innovative analytical methods to generate real-world evidence about the use and outcomes of prescribed medicines among people with opioid dependence. Awareness of harms in clinical settings and evaluating outcome risk during medicine use would give clinicians the ability to understand who needs prevention and treatment services, ensuring efforts and resources are targeted towards those most at-risk. These represent important strategies for improving quality medicine use and reducing harms among people with opioid dependence.